Legendary fund manager Cathie Wood has shifted her portfolio for the new year with evolving strategies. This week, it was ...

Cathie Wood's ARK ETFs have made a series of significant trades on Friday, February 14, 2025, continuing their dynamic investment strategy in the tech and biotech sectors. The most notable move was ...

It could get a whole lot harder to beat Cathie Wood’s Ark Invest line of funds moving forward as artificial intelligence (AI) ...

Tesla's overall business has more dimensions to it than that of Archer. Beyond EVs, it also produces energy storage packs and is current investing heavily in artificial intelligence (AI) -- primarily ...

GREAT SALE!!!!!! The 47th annual Stock Dog Sale sold 16 dogs, averaging $10,984, with a top of $23,000 to Pat Fulton Ranches of Bayside. The 63rd annual Gelding Sale sold 38 geldings, averaging ...

Cathy Wood joins Johns Hopkins as the inaugural Vice Dean for Finance and Administration at the Johns Hopkins University School of Medicine. › Johns Hopkins Medicine has announced that Cathy Wood has ...

19 Investigates first brought you news of an arrest in Catherine Parisi’s case Tuesday. Cathy Parisi’s daughters Cecelia and Angelina grew up without a mother. For years, they have not known ...

Robert F. Kennedy Jr., President Trump’s nominee to be health secretary, would have oversight power over the vaccine’s maker, Merck, if confirmed. By Christina Jewett and Sheryl Gay Stolberg ...

Parisi, who went by Cathy, was just 25 years old when she was last seen in April 1997. “The arrest is almost enough comfort just to know that, something has happened,” said Speer. Speer says ...

Speaking at the World Economic Forum 2025, Cathy Li, Head of AI, Data, and Metaverse at the World Economic Forum, highlighted the profound impact of generative AI on industries, businesses ...

Wood last played on 24 August in the first Test against Sri Lanka Fast bowler Mark Wood will play for the first time since August in England's first T20 against India in Kolkata on Wednesday. Wood ...

Moderna's recent stumbles make the company an acquisition target. Merck desperately needs Moderna's mRNA-based Personal Cancer Vaccines ("PCVs") to extend KEYTRUDA's patent protection beyond 2028.